M. Minocha

发表

Novel Dexamethasone-Loaded Nanomicelles for the Intermediate and Posterior Segment Uveitis

Ashim K. Mitra, A. Mitra, Mitan Gokulgandhi, 2014, AAPS PharmSciTech.

Transporter targeted drug delivery

A. Mitra, M. Minocha, N. Mandava, 2010 .

Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.

B. Qin, A. Mitra, M. Minocha, 2012, International journal of pharmaceutics.

Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus

A. Nader, A. Othman, M. Minocha, 2019, Clinical Pharmacokinetics.

Drug Development and Potential Regulatory Paths for Insulin Biosimilars

J. Gobburu, M. Minocha, 2014, Journal of diabetes science and technology.

Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.

B. Qin, A. Mitra, M. Minocha, 2012, International journal of pharmaceutics.

Effect of short term and chronic administration of Sutherlandia frutescens on pharmacokinetics of nevirapine in rats.

W. Folk, A. Mitra, M. Minocha, 2011, International journal of pharmaceutics.

Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials

A. Othman, M. Minocha, A. Suleiman, 2018, Clinical Pharmacokinetics.

Application of Exposure-Response Analyses to Establish the Pharmacodynamic Similarity of a Once-Daily Regimen to an Approved Twice-Daily Dosing Regimen for the Treatment of HCV Infection

P. Marroum, B. Hosmane, D. Cohen, 2017, The AAPS Journal.

Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials

A. Othman, M. Minocha, A. Suleiman, 2019, Clinical Pharmacokinetics.

Models of Variability and Circadian Rhythm in Heart Rate, Blood Pressure, and QT Interval for Healthy Subjects Who Received Placebo in Phase I Trials

Y. Chiu, A. Othman, M. Minocha, 2019, Clinical and translational science.

Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials

J. Sheridan, A. Othman, M. Minocha, 2015, Clinical Pharmacokinetics.

IMPROVED DELIVERY OF MOLECULARLY TARGETED AGENTS UPON MODULATION OF MULTIDRUG RESISTANCE EFFLUX PROTEINS AT MOUSE BLOOD BRAIN BARRIER

M. Minocha, 2012 .

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.

A. Kaser, O. Dewit, D. Franchimont, 2018, The lancet. Gastroenterology & hepatology.

609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)

R. Greil, J. Machiels, T. Dorff, 2020 .

Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus

A. Othman, M. Minocha, J. Medema, 2018, Clinical Pharmacokinetics.

Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors

A. Mitra, M. Minocha, Varun Khurana, 2014, Drug metabolism and drug interactions.

Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS).

A. Mitra, M. Minocha, Varun Khurana, 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals.

A. Mitra, M. Minocha, Deep Kwatra, 2011, Life sciences.

359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results

R. Govindan, A. Chiang, R. Salgia, 2020 .

Interaction of ocular hypotensive agents (PGF2 alpha analogs-bimatoprost, latanoprost, and travoprost) with MDR efflux pumps on the rabbit cornea.

G. Mishra, A. Mitra, S. Hariharan, 2009, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Novel Dexamethasone-Loaded Nanomicelles for the Intermediate and Posterior Segment Uveitis

A. Mitra, Ravi Vaishya, Mitan R. Gokulgandhi, 2014, AAPS PharmSciTech.

Leveraging magnetic resonance imaging - annualized relapse rate relationship to aid early decision making in multiple sclerosis clinical drug development

J. Gobburu, M. Gopalakrishnan, M. Minocha, 2015 .

Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate

J. Enejosa, A. Othman, M. Mohamed, 2020, Clinical pharmacology in drug development.

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

R. Govindan, Melissa L. Johnson, E. Felip, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors

A. Mitra, M. Minocha, Varun Khurana, 2014, Drug metabolism and drug interactions.

Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).

R. Govindan, T. Owonikoko, H. Borghaei, 2021 .

OA11.03 A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC

R. Govindan, A. Chiang, R. Salgia, 2021 .